To be a global partner for low and middle income countries in the provision of education, development and training for the safe, responsible and effective use of veterinary medicines and its subsequent benefit to environmental, animal and human welfare, and economic development.
Registered Charity Number: 1186100.
The appropriate worldwide regulation of veterinary medicines to ensure their responsible, safe and effective use, and consequent animal health, public health and economic benefits.
SMArt will positively impact on the welfare of animals, people and the environment.
SMArt is committed to being the trusted partner in the provision of unparrelled service to our customers, built on professionalism, integrity, expertise and honesty; truly believing success only comes when we work together.
SMArt’s values are:
SERVICE: We work for the benefit of our animals, people and planet.
METHOD: We use the right processes, behaviours, tools and techniques in delivery of our propositions.
ADVISORY: We share our knowledge and skills in collaboration with others.
RELIABLE: We always deliver what we promise.
TRUST: We embody integrity and confidentiality.
SMArt is a Charitable Incorporated Organisation. It is NOT a charitable arm of another organisation, it is a separate entity that can enter into contracts with its partners in its own right. As a foundation, it does not have a membership forum or member base, and therefore it’s Trustees have sole voting rights of the Foundation.
It has a governance framework and structure which oversee the charity and ensure its regulatory and legislative compliance, whilst furthering its charitable purpose.
Safe: A medicine must be safe to use protecting animals, people and the environment. As with human medicines, many veterinary medicines can have side effects. These must be carefully evaluated and the benefit of using the medicine must strongly outweigh any risks involved with its use. Human safety is always of paramount importance. Post authorisation surveillance activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other medicine-related problem, provides the basis for continuous benefit/risk assessment. Food security and adequate nutrition is a basic human right which is reliant on efficient food systems. Consumer safety for foods derived from animals is ensured by consideration of whether a medicine should be allowed, and if allowed enough time elapses from the time of medicine administration to the time when animal products are obtained, so that any residues of medicines drop to a safe level. This limit is known as the maximum residue limit (MRL) and the necessary time period is known as the withdrawal period. The withdrawal period is specific to each veterinary drug but is only reliable when the veterinary medicine is of a consistent quality, and is administered in a consistent manner, normally as approved during the medicine’s authorisation process.
Medicines: All medicines should be manufactured in authorised premises to approved standards. This ensures that all batches of the product meet the necessary standards and are consistent. These standards, similar to those for human medicines, check among other things that products are sterile if they need to be and that each tablet or bottle contains the correct amount of the active ingredient. It is important to ensure that the required standards are maintained and that products are being produced, stored and handled properly. There should be effective enforcement processes to detect and address when these standards fall below acceptable levels, and to make sure products can be withdrawn from sale to avoid causing harm. Medicines should do what they claim to do; as long as the instructions on the label are followed properly and they are given to the types of animal for which they were authorised.
Animals: Livestock are a crucial asset for any country. They play an essential role in creating livelihoods and food security. Maintenance of terrestrial and aquatic livestock health and welfare requires access to high quality, effective and reliable medicines for prevention and treatment of disease. Limited access and availability of quality veterinary drugs jeopardise not only livestock productivity through the inability to treat disease resulting in production losses, but also the ability to prevent and contain disease outbreaks including those diseases which can affect people (zoonoses). Antimicrobial treatment of animals may contribute to the development of resistant organisms, known as Antimicrobial Resistance (AMR), in the treated animals. Through the use, overuse, and misuse of antimicrobials, more and more microorganisms have become or are becoming resistant to the drugs to which they were previously susceptible. This is threatening the effectiveness of antimicrobials, particularly antibiotics, available to treat infections. Containing and controlling AMR requires coordinated national and international action across all stakeholders, including governments, international organisations, private businesses, farmers, investors, civil society, academia and philanthropy.
Regulatory Training: The appropriate regulation of veterinary medicines worldwide will ensure they are of good quality manufactured in a consistent manner and used responsibly, safely and effectively - leading to improved animal health, public health and economic benefits. End-to-end regulation encompasses: evidence based pre-authorisation assessment of medicines, including clinical trial data ongoing monitoring of quality control of production standards through testing of marketed medicine quality and inspections of manufacture and distribution sites ongoing monitoring of any adverse reactions or lack of effectiveness of medicines once on the market and active surveillance activities to protect consumers through, for example, testing of animal products (such as milk, meat, eggs) for residues and banned substances Effective regulation policy and activity are underpinned by a robust national legislative framework and through a governance structure that defines the roles and responsibilities of the varied stakeholders involved, from the national regulator through to the manufacturers and users of medicines. Building capacity and capability through regulatory training will positively impact on the welfare of animals, people and the environment. Committing to develop national and regional capability for regulating and enforcing regulations requires efforts to improve, converge and enforce appropriate standards and processes.
Connecting regulators with world leading expertise to assess needs and create tailored training programmes. Our programmes encompass confidential benchmarking, policy development, expert scientific advice and tools in the following areas:
Lord Trees is a veterinary surgeon, emeritus Professor of Veterinary Parasitology at the University of Liverpool and elected crossbench Peer since 2012. He has previously served as Dean of the Faculty of Veterinary Science at Liverpool University (2001-2008), Vice-President of the European Veterinary Parasitology College (2006-2009), President of the Royal College of Veterinary Surgeons (2009-2010), and has Chaired the Moredun Research Institute since 2011. He brings a wealth of experience and expertise in neglected tropical diseases, international animal health, welfare and policy.
David is a Non-Executive Director at the Veterinary Medicines Directorate and chairs its Audit and Risk Assurance Committee. As a qualified accountant and former Director at the National Audit Office the charity will be able to draw on the experience of his financial and audit background. David has extensive experience helping to provide assurance to public sector bodies on their financial and operational performance.Learn more
Lois is Director of Operational Support & External Affairs for Global Alliance for Livestock Veterinary Medicines, GALVmed, a not-for-profit animal health product development and access partnership. Notably, Lois leads the implementation of a project that has harmonised the registration requirements of veterinary medicines across countries in the East African Community and developed a Mutual Recognition Procedure. As a lawyer, and with vast policy and advocacy experience in developing countries in the veterinary field, Lois will use her wide network and expertise in stakeholder engagement, public private partnerships and public policy to help the charity achieve its objectives.Learn more
Pete has had a long career in research and headed up human and veterinary national institutions. These have included the Public Health Laboratory Service Central Public Health Laboratories, the Health Protection Agency Centre for Infections, the Veterinary Laboratories Agency, and is currently Chief Executive of the Veterinary Medicines Directorate. He has a long record of chairing national and international committees and was the first chair of the World Health Organisation Laboratory Twinning Programme developing capability in low and middle income countries to improve compliance with the International Health Regulations.Learn more
A veterinarian with longstanding experience in veterinary research and development based on 45 years employed in private practice, academia, public sector, industry and consultancy services. His specialisms are in animal fertility and veterinary vaccine development and regulation. Over the last 10-12 years he has been working mostly in animal health and productivity in lower and middle income countries and has worked with several NGOs and charities in this field. He is currently Director of Supporting Evidence Based Interventions (SEBI-livestock) a programme funded by the Bill and Melinda Gates Foundation. He is delighted to be working with SMArt as his background will enable him to make a significant contribution to this critical field of international development.Learn more
Abi has held several senior roles across government spanning policy, operational delivery and major project management, including recently the Veterinary Medicines Directorate’s Programme Director for EU Exit. As the current Director of Authorisations, Abi supports the CEO with corporate strategy management and oversees the department leading on scientific benefit:risk assessment of applications for veterinary medicines and management of the R&D programme on behalf of Defra. Abi led the development of the VMD’s international work in providing regulatory training to other national competent authorities and undertaking sponsored project work, most recently in Sub-Saharan Africa.Learn more
Please contact us by using the form below: